Human amniotic epithelial cells (h-AECs), which have various merits as a cell source for cell
therapy, are known to differentiate into cardiomyocytes in vitro. However, the ability of h …

Human amniotic epithelial cells (h-AECs) have been shown to differentiate into
cardiomyocyte-like cells in vivo that can regenerate myocardial tissue and improve cardiac …

Human amniotic fluid stem cells (hAFSCs) derived from second-trimester amniocentesis
were evaluated for the therapeutic potential of cardiac repair. Whether hAFSCs can be …

Introduction: Human amnion-derived mesenchymal stem cells (hAMSCs) have been used in
the treatment of acute myocardial infarction. In the current study, we investigated the efficacy …

Rationale: Amniotic membrane is known to have the ability to transdifferentiate into multiple
organs and is expected to stimulate a reduced immunologic reaction. Objective: Determine …

BACKGROUND: Embryonic stem (ES) cell–derived cardiomyocytes transplantation and
tissue engineering together represent a promising approach for the treatment of myocardial …

In recent years, various types of stem cells have been characterized and their potential for
cardiac regeneration has been investigated. We have previously described the isolation of …

Objective: To test the hypothesis that human embryonic stem cells (hESCs) can be guided to
form new myocardium by transplantation into the normal or infarcted heart, and to assess the …

Objective: Transplantation of stem cells in the acute ischemic myocardium (AMI) may play a
role in the recovery of cardiac function. Here, we investigated the ability of amniotic fluid …

Cell therapy has developed as a complementary treatment for myocardial regeneration.
While both autologous and allogeneic uses have been advocated, the ideal candidate has …